+Follow
Patpatliao
No personal profile
3
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
Patpatliao
08-08
Great article, would you like to share it?
@OptionsAura:Iron Condor - Profiting from $NVO Earnings with Options
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":4161864768210492,"uuid":"4161864768210492","gmtCreate":1698761784472,"gmtModify":1723047474544,"name":"Patpatliao","pinyin":"patpatliao","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/9d848a0f03d46493f9f6a2377a9d9d60","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":3,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"23f878ed27704312ae41c7f17e73b319-2","templateUuid":"23f878ed27704312ae41c7f17e73b319","name":"Annualised return","description":"Top 30%","bigImgUrl":"https://community-static.tradeup.com/news/50461c8139b6ca50fe2dae19aa769b25","smallImgUrl":"https://community-static.tradeup.com/news/c8eef504853d5a517c50d7a88fa5c1e1","grayImgUrl":"https://community-static.tradeup.com/news/5273727845028b8d9b65556bdcb217b9","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5300}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":335906630554032,"gmtCreate":1723046922254,"gmtModify":1723047436697,"author":{"id":"4161864768210492","authorId":"4161864768210492","authorIdStr":"4161864768210492","name":"Patpatliao","avatar":"https://community-static.tradeup.com/news/9d848a0f03d46493f9f6a2377a9d9d60","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4161864768210492"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/335906630554032","repostId":"335873339588648","repostType":1,"repost":{"id":335873339588648,"gmtCreate":1723036082051,"gmtModify":1723036143498,"author":{"id":"10000000000010922","authorId":"10000000000010922","authorIdStr":"10000000000010922","name":"OptionsAura","avatar":"https://static.tigerbbs.com/f27744c1fabf17b5f44122ab53e7da10","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"10000000000010922"},"themes":[],"title":"Iron Condor - Profiting from $NVO Earnings with Options","htmlText":"In recent years, <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> has been one of the best-performing pharmaceutical stocks on the U.S. market. Even during the broad market correction of 2022, NVO's stock surged over 20% thanks to the blockbuster weight loss drug Wegovy. Since early 2019, the stock has skyrocketed more than sixfold. NVO's impressive performance is closely tied to its strong earnings reports, which often signal profitable trading or investment opportunities.Over the past two years, NVO's earnings growth has been explosive. With products like Wegovy, a GLP-1 class drug for diabetes and obesity management, the company's growth has accelerated. Revenue grew over 25% in 2022 and more than 30% in 2023, with net profit soaring over 50% year-over-year in 2023.Howe","listText":"In recent years, <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> has been one of the best-performing pharmaceutical stocks on the U.S. market. Even during the broad market correction of 2022, NVO's stock surged over 20% thanks to the blockbuster weight loss drug Wegovy. Since early 2019, the stock has skyrocketed more than sixfold. NVO's impressive performance is closely tied to its strong earnings reports, which often signal profitable trading or investment opportunities.Over the past two years, NVO's earnings growth has been explosive. With products like Wegovy, a GLP-1 class drug for diabetes and obesity management, the company's growth has accelerated. Revenue grew over 25% in 2022 and more than 30% in 2023, with net profit soaring over 50% year-over-year in 2023.Howe","text":"In recent years, $Novo-Nordisk A/S(NVO)$ has been one of the best-performing pharmaceutical stocks on the U.S. market. Even during the broad market correction of 2022, NVO's stock surged over 20% thanks to the blockbuster weight loss drug Wegovy. Since early 2019, the stock has skyrocketed more than sixfold. NVO's impressive performance is closely tied to its strong earnings reports, which often signal profitable trading or investment opportunities.Over the past two years, NVO's earnings growth has been explosive. With products like Wegovy, a GLP-1 class drug for diabetes and obesity management, the company's growth has accelerated. Revenue grew over 25% in 2022 and more than 30% in 2023, with net profit soaring over 50% year-over-year in 2023.Howe","images":[{"img":"https://community-static.tradeup.com/news/13d357062ad8e408fa5f9e888d605d44","width":"560","height":"240"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/335873339588648","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":61,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":335906630554032,"gmtCreate":1723046922254,"gmtModify":1723047436697,"author":{"id":"4161864768210492","authorId":"4161864768210492","authorIdStr":"4161864768210492","name":"Patpatliao","avatar":"https://community-static.tradeup.com/news/9d848a0f03d46493f9f6a2377a9d9d60","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4161864768210492"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/335906630554032","repostId":"335873339588648","repostType":1,"repost":{"id":335873339588648,"gmtCreate":1723036082051,"gmtModify":1723036143498,"author":{"id":"10000000000010922","authorId":"10000000000010922","authorIdStr":"10000000000010922","name":"OptionsAura","avatar":"https://static.tigerbbs.com/f27744c1fabf17b5f44122ab53e7da10","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"10000000000010922"},"themes":[],"title":"Iron Condor - Profiting from $NVO Earnings with Options","htmlText":"In recent years, <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> has been one of the best-performing pharmaceutical stocks on the U.S. market. Even during the broad market correction of 2022, NVO's stock surged over 20% thanks to the blockbuster weight loss drug Wegovy. Since early 2019, the stock has skyrocketed more than sixfold. NVO's impressive performance is closely tied to its strong earnings reports, which often signal profitable trading or investment opportunities.Over the past two years, NVO's earnings growth has been explosive. With products like Wegovy, a GLP-1 class drug for diabetes and obesity management, the company's growth has accelerated. Revenue grew over 25% in 2022 and more than 30% in 2023, with net profit soaring over 50% year-over-year in 2023.Howe","listText":"In recent years, <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> has been one of the best-performing pharmaceutical stocks on the U.S. market. Even during the broad market correction of 2022, NVO's stock surged over 20% thanks to the blockbuster weight loss drug Wegovy. Since early 2019, the stock has skyrocketed more than sixfold. NVO's impressive performance is closely tied to its strong earnings reports, which often signal profitable trading or investment opportunities.Over the past two years, NVO's earnings growth has been explosive. With products like Wegovy, a GLP-1 class drug for diabetes and obesity management, the company's growth has accelerated. Revenue grew over 25% in 2022 and more than 30% in 2023, with net profit soaring over 50% year-over-year in 2023.Howe","text":"In recent years, $Novo-Nordisk A/S(NVO)$ has been one of the best-performing pharmaceutical stocks on the U.S. market. Even during the broad market correction of 2022, NVO's stock surged over 20% thanks to the blockbuster weight loss drug Wegovy. Since early 2019, the stock has skyrocketed more than sixfold. NVO's impressive performance is closely tied to its strong earnings reports, which often signal profitable trading or investment opportunities.Over the past two years, NVO's earnings growth has been explosive. With products like Wegovy, a GLP-1 class drug for diabetes and obesity management, the company's growth has accelerated. Revenue grew over 25% in 2022 and more than 30% in 2023, with net profit soaring over 50% year-over-year in 2023.Howe","images":[{"img":"https://community-static.tradeup.com/news/13d357062ad8e408fa5f9e888d605d44","width":"560","height":"240"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/335873339588648","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":61,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}